SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community members intensely debate Donald Trump's recent State of the Union address, fueling highly polarized opinions regarding his economic claims and the political implications for his media company.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as investors digest reported earnings, which showed revenue growth but wider losses, alongside a significant workforce reduction aimed at improving profitability. The community is actively debating the company's substantial cash burn and the ongoing leadership situation, balanced by discussion around increasing production efficiency and future EV model launches.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending amidst a battle between bullish enthusiasm for its reported $8.5 billion Meta-backed loan for AI infrastructure expansion and bearish concerns over its credit profile after reports of difficulty securing financing for another data center, a claim the company denies. The market is sharply divided ahead of upcoming earnings, with many anticipating a significant AI-driven rally while others fear potential debt-related headwinds, also closely watching NVIDIA's sector-influencing report.

Pieverse

PIEVERSE CRYPTO is trending due to reports of a significant short squeeze and liquidations, coupled with observations of quiet accumulation. The community is actively discussing PIEVERSE's distinction as the "true pie universe" amidst broader concerns around "Pi Coin" scams.

FIST is the governance token of FstSwap, a decentralized exchange protocol based on BSC Binance Smart Chain, with a total of 200 million tokens in full circulation

Fistbump

FIST CRYPTO is trending as it's being heavily tagged alongside promotional messages for the newly launched MIGA token, with the community actively discussing an immediate airdrop opportunity for those who purchase MIGA.

MEFAI is an institutional-grade trading intelligence system leveraging AI to process high-frequency data streams from on-chain activity, derivatives markets, order book depth, and behavioral sentiment. It delivers real-time structural market bias signals for strategic decision-making. Designed for professionals, MEFAI eliminates emotional bias and provides a transparent, rules-based edge in modern algorithmic environments.

META FINANCIAL AI

MEFAI is trending as community discussions revolve around the launch and rapid promotion of a new token, MIGA, with users actively participating in airdrop incentives and highlighting its initial momentum, while also mentioning MEFAI itself as a low-cap prospect.

Binance Coin is the cryptocurrency of the Binance platform. It is a trading platform exclusively for cryptocurrencies. The name "Binance" is a combination of binary and finance.  Thus, the startup name shows that only cryptocurrencies can be traded against each other. It is not possible to trade crypto currencies against Fiat. The platform achieved an enormous success within a very short time and is focused on worldwide market with Malta headquarters. The cryptocurrency currently has a daily trading volume of 1.5 billion - 2 billion US dollars and is still increasing.  In total, there will only be 200 million BNBs. Binance uses the ERC20 token standard from Ethereum and has distributed it as follow: 50% sold on ICO, 40% to the team and 10% to Angel investors. The coin can be used to pay fees on Binance. These include trading fees, transaction fees, listing fees and others. Binance gives you a huge discount when fees are paid in BNB.   The schedule of BNB fees discount is as follow: In the first year, 50% discount on all fees, second year 25% discount, third year 12.5% discount, fourth year 6.75 % discount, and from the fifth year onwards there is no discount. This structure is used to incentivize users to buy BNB and do trades within Binance.  Binance announced in a buyback plan that it would buy back up to 100 million BNB in Q1 2018. The coins are then burned. This means that they are devaluated to increase the value of the remaining coins. This benefits investors. In the future, the cryptocurrency will remain an asset on the trading platform and will be used as gas.  Other tokens that are issued by exchanges include Bibox Token, OKB, Huobi Token, and more.

Binance

BNB is actively discussed for its expansion into tokenized stock products and new institutional integrations for off-exchange collateral, signaling a deeper push into traditional finance. However, significant community skepticism persists amid allegations of market manipulation and ongoing regulatory challenges for the exchange.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is actively discussed due to a potential short squeeze, fueled by Tether's increasing ownership and substantial investment commitments for advertising and cloud services, alongside its strategic acquisition of Northern Data for AI infrastructure and the rollout of its 'Rumble Shorts' feature.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending amid robust community discussion around its ANKTIVA cancer treatment and intense short squeeze speculation, fueled by ongoing international regulatory progress and anticipation of further corporate developments. Investors are highly optimistic about the company's scientific advancements and its potential global market impact.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is trending with multiple bullish analyst ratings and high price targets for its lead candidate AVTX-009, which has completed enrollment in its Phase 2 trial for hidradenitis suppurativa. The community is actively discussing the stock's significant upside potential in the competitive autoimmune disease market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AC Immune (NASDAQ:ACIU) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of AC Immune from a "hold" rating to a "sell" rating in a research note on Saturday...

AC Immune (NASDAQ:ACIU) Stock Price Down 5.4% - Time to Sell?

AC Immune (NASDAQ:ACIU) Trading Down 5.4% - Here's Why...

Short Interest in AC Immune (NASDAQ:ACIU) Grows By 94.4%

AC Immune (NASDAQ:ACIU - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 3,593,227...

AC Immune (NASDAQ:ACIU) Trading Up 5% - Should You Buy?

AC Immune (NASDAQ:ACIU) Trading 5% Higher - Here's What Happened...

<ul class="summary-bullets"><li>The trial results showed for the first time that active immunotherapy targeting a-syn pathology could slow the progression of Parkinson’s disease.&nbsp;</li><li>The interim results from the study showed a 100% responder rate for all targets.</li><li>ACIU plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp; &nbsp;</li></ul>AC Immune SA (ACIU) shares surged on Thursday morning after the biopharma company announced positive results from the interim Phase 2 study of its early Parkinson’s disease treatment.&nbsp;The company said that the results of the VacSYn trial of ACI-7104.056 showed, for the first time, that targeting a-syn pathology with an active immunotherapy could possibly slow the progression of Parkinson’s disease.&nbsp;Shares of&nbsp;<a href="https://stocktwits.com/symbol/ACIU">ACIU</a> surged over 23% in pre-market trading after the announcement.&nbsp;“The interim Phase 2 data shows the potential of our ACI-7104.056 active immunotherapy to slow the progression of Parkinson’s disease and hold the promise of a tremendous step forward for millions of patients,” said Andrea Pfeifer, CEO of AC Immune SA. Pfeifer added that the strong results would be a basis for accelerating the development of the treatment.&nbsp;<h2 class="st-heading-2">Study Results</h2>The interim results from the study showed that the company’s new treatment had a 100% responder rate, meaning all participants had the expected immune response across all immunogenicity measures used.There were no clinically relevant or serious adverse effects to the drug apart from routine side effects such as injection site reactions, headaches, and fatigue, as reported by some participants.&nbsp;Final results from the Part 1 trial are expected in mid-2026, and the company plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp;<h2 class="st-heading-2">How Are Stocktwits Users Reacting?</h2>On Stocktwits, retail sentiment around ACIU jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped to ‘extremely high’ from ‘normal’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1282/158;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_7_36_27_PM_png_161653af50.webp" alt="ACIU sentiment and message volume" width="1282" height="158"></figure>Shares of ACIU are up over 31% in the past six months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CHINA - 2025/10/02: In this photo illustration, the AC Immune logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is AC Immune Stock Up Over 23% Today?

ACIU shares surged over 23% after the company announced positive results from an interim Phase 2 study. 

Equity

FY2025 EPS Estimates for AC Immune Lifted by HC Wainwright

AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for AC Immune in a report issued on Wednesday, November 5th. HC...

FY2025 EPS Estimates for AC Immune Raised by Leerink Partnrs

AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for AC Immune in a research note issued on Wednesday, November...

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.22	--	--	N/A
Q3 '25	-$0.23	-$0.17	27.05%	BEAT
Q2 '25	-$0.22	-$0.26	-19.10%	MISSED
Q1 '25	-$0.23	-$0.24	-1.59%	MISSED
Q4 '24	-$0.21	--	--	N/A

ACIU
AC Immune SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ACIU News

ACIUAC Immune SA